IONIS PHARMACEUTICALS INC
IONSAPI behind this page
IONS FY 2025 request
Playground key active
/api/financials?ticker=IONS&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 943,711 | 705,138 | +33.8% |
Show Product Lines breakouts |
|||
| Collaborative Agreement Revenue [Member] | 465,785 | 332,647 | +40.0% |
| Commercial Revenue [Member] | 435,848 | 293,076 | +48.7% |
| DAWNZERA Sales [Member] | 7,789 | — | — |
| Other Commercial Revenue [Member] | 35,004 | 35,769 | -2.1% |
| Other Royalties [Member] | 24,159 | 21,010 | +15.0% |
| Product | 115,315 | — | — |
| Research and Development Revenue [Member] | 507,863 | 412,062 | +23.2% |
| Royalty | 285,529 | 257,307 | +11.0% |
| SPINRAZA Royalties [Member] | 212,280 | 216,090 | -1.8% |
| TRYNGOLZA Sales [Member] | 107,526 | — | — |
| WAINUA Joint Development Revenue [Member] | 42,078 | 79,415 | -47.0% |
| WAINUA Royalties [Member] | 49,090 | 20,207 | +142.9% |
Show Business Segments breakouts |
|||
| Ionis Operations [Member] | 943,711 | 705,138 | +33.8% |
Show Type Of Arrangement breakouts |
|||
| Alnylam [Member] | 7,880 | 8,110 | -2.8% |
| AstraZeneca [Member] | 147,295 | 129,759 | +13.5% |
| Biogen [Member] | 289,194 | 368,058 | -21.4% |
| Novartis [Member] | 4,804 | 37,762 | -87.3% |
| Ono [Member] | 284,498 | — | — |
| Otsuka [Member] | 21,635 | 46,856 | -53.8% |
| Roche [Member] | 7,781 | 39,871 | -80.5% |
| Cost of Revenue | 15,909 | 11,215 | +41.9% |
Show Business Segments breakouts |
|||
| Ionis Operations [Member] | 14,008 | 10,415 | +34.5% |
| Total Costs & Expenses | 1,325,395 | 1,180,219 | +12.3% |
| Research & Development | 915,619 | 901,530 | +1.6% |
| Selling, General & Administrative | 393,867 | 267,474 | +47.3% |
Show Business Segments breakouts |
|||
| Ionis Operations [Member] | 351,992 | 230,478 | +52.7% |
| Operating Income | -381,684 | -475,081 | +19.7% |
| Other Non-Operating Income (Expense) | -15,358 | 1,331 | -1253.9% |
| Income Before Taxes | -379,601 | -460,068 | +17.5% |
| Income Tax Expense (Benefit) | -1,786 | 6,171 | -128.9% |
| Net Income | -381,387 | -453,897 | +16.0% |
Show Business Segments breakouts |
|||
| Ionis Operations [Member] | -381,387 | -453,897 | +16.0% |
Show Equity Components breakouts |
|||
| Retained Earnings | -381,387 | -453,897 | +16.0% |
| Comprehensive Income | -375,857 | -452,063 | +16.9% |
| EPS (Basic) | -2.38 | -3.04 | +21.7% |
| EPS (Diluted) | -2.38 | -3.04 | +21.7% |
| Wtd Avg Shares (Basic) | 160,010 | 149,514 | +7.0% |
| Wtd Avg Shares (Diluted) | 160,010 | 149,514 | +7.0% |
| Gain Loss On Investments | 10,220 | -2,889 | +453.8% |
| Interest Expense | -17,262 | -16,994 | -1.6% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 372,260 | 242,077 | +53.8% |
| Short-Term Investments | 2,305,176 | 2,055,579 | +12.1% |
| Inventory | 10,048 | 12,512 | -19.7% |
| Total Current Assets | 2,990,635 | 2,620,290 | +14.1% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 123,048 | 94,251 | +30.6% |
Show Property Plant And Equipment By Type breakouts |
|||
| Property, Plant and Equipment, Excluding Land [Member] | 123,048 | 85,682 | +43.6% |
| Operating Lease Right-of-Use Assets | 238,549 | 161,856 | +47.4% |
| Other Non-Current Assets | 171,604 | 127,278 | +34.8% |
| Total Assets | 3,523,836 | 3,003,675 | +17.3% |
| Current Liabilities | |||
| Accounts Payable | 28,082 | 42,964 | -34.6% |
| Accrued Liabilities | 106,089 | 108,438 | -2.2% |
| Deferred Revenue (Current) | 73,761 | 78,989 | -6.6% |
| Current Portion of Long-Term Debt | -432,120 | — | — |
| Total Current Liabilities | 781,567 | 309,318 | +152.7% |
| Non-Current Liabilities | |||
| Long-Term Debt | 1,812,405 | — | — |
| Long-Term Debt | 1,327,999 | — | — |
| Operating Lease Liabilities | 262,383 | 161,805 | +62.2% |
| Total Liabilities | 3,034,747 | 2,415,324 | +25.6% |
| Contract With Customer Liability Noncurrent | 92,001 | 156,504 | -41.2% |
| Stockholders' Equity | |||
| Common Stock | 163 | 158 | +3.2% |
| Retained Earnings | -2,631,195 | -2,249,808 | -17.0% |
| Accumulated Other Comprehensive Income | -25,281 | -30,811 | +17.9% |
| Total Stockholders' Equity | 489,089 | 588,351 | -16.9% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -25,281 | -30,811 | +17.9% |
| Additional Paid In Capital | 3,145,402 | 2,868,812 | +9.6% |
| Common Stock | 163 | 158 | +3.2% |
| Retained Earnings | -2,631,195 | -2,249,808 | -17.0% |
| Total Liabilities & Equity | 3,523,836 | 3,003,675 | +17.3% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 133,874 | 130,200 | +2.8% |
| Change in Inventory | -13,674 | -5,071 | -169.7% |
| Change in Accounts Payable | -15,360 | 15,990 | -196.1% |
| Change in Deferred Revenue | -69,731 | -156,819 | +55.5% |
| Net Cash from Operations | -268,583 | -500,947 | +46.4% |
| Investing Activities | |||
| Capital Expenditures | -51,444 | -45,280 | -13.6% |
| Purchases of Investments | -1,918,562 | -1,852,858 | -3.5% |
| Net Cash from Investing | -277,776 | -134,027 | -107.3% |
| Financing Activities | |||
| Debt Issuance Costs (FY) | — | — | — |
Show Debt Instrument breakouts |
|||
| 0% Notes due 2030 [Member] | -18,949 | — | — |
| Amortization of Financing Costs | 6,908 | 6,690 | +3.3% |
Show Debt Instrument breakouts |
|||
| Convertible Senior Notes [Member] | 6.3 | 6.1 | +3.3% |
| Net Cash from Financing | 675,840 | 478,058 | +41.4% |
| Supplemental | |||
| Income Taxes Paid | -639 | -5,620 | +88.6% |
| Interest Paid | 10,782 | 10,869 | -0.8% |
| Unpaid Capital Expenditures | 478 | 947 | -49.5% |
| Other Cash Flow | |||
| Net Change in Cash | 130,183 | -157,189 | +182.8% |
Values in thousands USD. Source: SEC EDGAR 10-K filing.